Folliculitis Decalvans Responsive to Tofacitinib: A Case Series

The case series documented the responsiveness of folliculitis decalvans to tofacitinib treatment. The study was conducted by Rebekka Jerjen and colleagues at Sinclair Dermatology in East Melbourne, Victoria, Australia. Although the article did not provide an abstract, it highlighted the potential effectiveness of tofacitinib, a Janus kinase inhibitor, in treating this chronic scalp condition characterized by inflammation and hair loss. The findings suggested that tofacitinib could be a promising therapeutic option for patients suffering from folliculitis decalvans, offering a new avenue for managing this challenging dermatological issue.